HCG Cancer Hospital Bengaluru, one of India’s leading cancer care chains, has announced a groundbreaking pilot study to transform the treatment landscape for head and neck cancer patients with Low Dose Immunotherapy.

As part of the pilot study, a total of 12 cases were studied between the age group of 54 to 76 years. All twelve patients from Bengaluru experienced significant tumor reduction of over 90 per cent, providing an economical and side-effect-free therapy through low-dose immunotherapy. In the pilot study, standard neoadjuvant chemotherapy is combined with low-dose Nivolumab immunotherapy, administering 40 mg every two weeks, as opposed to the full dose of 3 mg per kg of body weight. It has a potential role in improving the quality of life and longevity of patients with locally advanced carcinoma of the buccal mucosa.

Speaking to media, Dr B S Ajaikumar, Executive Chairman of Healthcare Global Enterprises Limited, said, "This study has the potential to be a game-changer in the sphere of head and neck cancer treatment. The initiative reflects HCG's commitment to advancing research and academia in India, positioning the organisation as a leader in this vital healthcare domain."

Dr Satheesh C T, Consultant - Medical and Hemato Oncology, Director of Clinical Trials HCG Cancer Hospital Bangalore, said, "This study presents a cost-effective solution without compromising the quality of care. This approach not only delivers promising clinical results but also in a manner that is highly economical for patients."

Enthused by these promising findings, HCG will initiate a study to explore the potential benefits of low-dose immunotherapy alongside neoadjuvant chemotherapy in head and neck cancers. Through this study spanning across multiple HCG centres in India, HCG will strive to unfold a highly effective and affordable cancer treatment option in the management of head and neck cancers.